The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer. The U.S. Food and Drug Administration (FDA) has granted orphan drug ...
FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings. HCB101, a novel Fc-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results